Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.

Imfinzi (durvalumab) - AstraZeneca

Kaitanni (cadonilimab) - Akesobio

Tevimbra (tislelizumab-jsgr) - BeOne Medicines

AiRuiKa (camrelizumab) - Elevar Therapeutics

Tyvyt (sintilimab) - Innovent Biologics, Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42371261

Aizong Shen; Kunkun Ge; Tongming Zhu; Yingqi Wu

Jun 30, 2026